ClinicalTrials.gg
RecruitingNCT06962176MIVANTUpdated Oct 26, 2026

Posterior Mitral Isthmus Line With Vein of Marshall Ethanolisation Compared With Anterior Mitral Lines in Patients With Persistent Atrial Fibrillation

An interventional study of Anterior Mitral Line Ablation and Posterior Mitral Isthmus Ablation with Vein of Marshall Ethanol Infusion in Persistent Atrial Fibrillation, sponsored by AZ Sint-Jan AV. Recruiting at 1 site in Belgium. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by AZ Sint-Jan AV · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 26, 2026Now RecruitingFirst site in Belgium+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
146
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Atrial Fibrillation by AZ Sint-Jan AV — 3 open to participants now, 3 under way, none of them phase 3. Atrial Fibrillation · AZ Sint-Jan AV.

Planned enrollment
4th of 11
146 · median 105
Started
2026
the only one that year
No phase
9 of 11
2 open now
Registered
11th of 11
by date

Among the 11 studies in Atrial Fibrillation by AZ Sint-Jan AV, this one is the 4th largest by planned enrollment, is the only one that started in 2026, is one of 9 with no phase, and was the 11th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Atrial Fibrillation by AZ Sint-Jan AV, or all of them as a file.
02

Study summary

The goal of this clinical study is to find out which treatment works best for people with persistent atrial fibrillation (a type of irregular heartbeat). Researchers are comparing two types of heart ablation procedures:

  • An anterior mitral line ablation (a treatment at the front part of the heart)
  • A posterior mitral line ablation (at the back of the heart), sometimes with an extra step using a small vein called the Vein of Marshall

The main questions the study aims to answer are:

  • Which approach works better at fixing the heart rhythm?
  • Which approach is safer (less complications)?

People who take part in this study will:

  • Undergo an ablation procedure as part of their standard care
  • Attend follow-up visits at 1, 3, and 6 months
  • Have tests like ECGs, heart ultrasound (echocardiogram), blood tests, heart rhythm monitors (Holter), and a heart CT scan
Read the detailed description

The MIVANT trial aims to compare two different strategies for treating patients with persistent atrial fibrillation (AF) using catheter ablation techniques. AF is a common heart rhythm disorder, and in persistent forms, it often does not respond adequately to pulmonary vein isolation (PVI) alone. For this reason, many patients require additional ablation lines in the left atrium to reduce arrhythmia recurrence and improve long-term rhythm control.

One such ablation strategy involves creating a linear lesion across the mitral isthmus-a region between the mitral valve and the pulmonary veins. There are two main anatomical approaches to target this area:

  • The anterior mitral line, which connects the right superior pulmonary vein to the mitral annulus
  • The posterior mitral line, which connects the left inferior pulmonary vein to the mitral annulus

The posterior line is technically more challenging because of the complex anatomy, proximity to blood vessels, and epicardial electrical pathways that can bypass endocardial lesions. However, this difficulty can be addressed by a technique known as Vein of Marshall (VOM) ethanol infusion. The VOM is a small vein near the mitral isthmus that contains nerve fibers and muscle bundles involved in atrial arrhythmias. Infusing ethanol into this vein can help create more effective and lasting ablation lines by reaching areas that standard catheter ablation cannot.

The MIVANT study will enroll 146 adult patients with persistent atrial fibrillation who are already scheduled to receive additional ablation beyond PVI. Patients will be randomized in a 1:1 ratio to undergo either:

  • A posterior mitral line ablation, with or without ethanol infusion into the Vein of Marshall, depending on anatomical feasibility
  • An anterior mitral line ablation without ethanol infusion

All procedures will be performed under general anesthesia or conscious sedation, using state-of-the-art mapping and ablation tools. Standardized ablation parameters will be followed to ensure consistency and quality across sites.

The main objective of this study is to determine whether the posterior approach-with possible VOM infusion-leads to a higher success rate of procedural bidirectional block across the mitral line, compared to the anterior approach.

Secondary objectives include assessing:

  • Safety outcomes such as bleeding, stroke, or coronary artery injury
  • Efficiency of the procedure, including total time, fluoroscopy exposure, and number of lesions needed
  • Recurrence of atrial arrhythmias at 6 months
  • Patient quality of life
  • Hospitalizations related to cardiovascular events

Participants will attend follow-up visits at 1, 3, and 6 months, during which they will undergo tests such as ECGs, echocardiography, Holter monitoring, CT coronary angiography, and blood tests.

This study is expected to last a total of 24 months, with 18 months allocated for patient recruitment and a minimum of 6 months follow-up per participant. The study is coordinated by AZ Sint-Jan Brugge AV in Belgium, with possible collaboration from other high-volume centers in France and Switzerland.

The findings of the MIVANT study will help clarify whether posterior mitral isthmus ablation-with the aid of Vein of Marshall ethanolisation-is a more effective and equally safe alternative to the anterior approach in the treatment of persistent atrial fibrillation.

03

Conditions studied

  • Persistent Atrial Fibrillation

Browse trials for

Keywords

  • Persistent Atrial Fibrillation
  • Catheter ablation
  • Vein of Marshall ethanolization
  • Mitral line ablation
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients between the ages of 18 and 80 years, diagnosed with symptomatic persistent AF with clinical indication for left atrial ablation with a mitral isthmus line. Pulmonary vein will be isolated in all patients before starting the mitral isthmus line (during a previous or the same procedure)

Exclusion criteria

Exclusion Criteria:

  • Previous mitral line or any other left atrial ablation beyond pulmonary vein isolation
  • Left atrial (LA) thrombus. LA thrombus can be determined by preprocedural imaging: CT, transesophageal echocardiography or MRI.
  • LA diameter greater than 60 mm on long axis parasternal view, or left atrial volume more than 250 cc.
  • \<25%.
  • Cardiac surgery within the previous 90 days.
  • Expecting cardiac transplantation or other cardiac surgery within 180 days.
  • Percutaneous transluminal coronary angioplasty/stenting or myocardial infarction within the previous 30 days.
  • Documented history of a thromboembolic event within the previous 60 days.
  • Diagnosed atrial myxoma.
  • Significant restrictive, constrictive, or with chronic symptoms.
  • Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment
  • Women who are pregnant or who plan to become pregnant during the study.
  • Acute illness or active infection at time of index procedure
  • Renal insufficiency
  • Unstable angina.
  • History of blood clotting or bleeding abnormalities.
  • to anticoagulation.
  • less than 1 year.
  • Uncontrolled heart failure.
  • Presence of a condition that precludes vascular access.
  • (INR) greater than 4 within 24 hours of procedure - for patients taking warfarin.
  • Unwilling or unable to provide .
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
146 participants (estimated)

Study arms

  • Experimental
    Anterior Mitral Line Ablation

    First pulmonary vein isolation (PVI) is performed - either as a first-time isolation (index procedure) or a re-isolation (in repeat procedures). Then a linear lesion is created on the anterior wall of the left atrium, from the roof line to the mitral annulus.

    Procedure: Anterior Mitral Line Ablation

  • Experimental
    Posterior Mitral Isthmus Ablation with Vein of Marshall Ethanol Infusion

    As with the anterior approach, pulmonary vein isolation (PVI) is systematically carried out before any additional ablation lines are created - either as initial isolation or re-isolation. In this group the posterior mitral isthmus, a region between the left inferior pulmonary vein and the mitral annulus, is targeted. Endocardial ablation using a dual energy catheter (RF and PF) is combined with ethanol infusion in the vein of Marshall (VOM), which ablates the adjacent epicardial tissue to enhance lesion durability.

    Procedure: Posterior Mitral Isthmus Ablation with Vein of Marshall Ethanol Infusion

Interventions

  • ProcedureAnterior Mitral Line Ablation

    First pulmonary vein isolation (PVI) is performed - either as a first-time isolation (index procedure) or a re-isolation (in repeat procedures). Then a linear lesion is created on the anterior wall of the left atrium, from the roof line to the mitral annulus.

  • ProcedurePosterior Mitral Isthmus Ablation with Vein of Marshall Ethanol Infusion

    Pulmonary vein isolation (PVI) is systematically carried out before any additional ablation lines are created - either as initial isolation or re-isolation. In this group the posterior mitral isthmus, a region between the left inferior pulmonary vein and the mitral annulus, is targeted. Endocardial ablation using a dual energy catheter (RF and PF) is combined with ethanol infusion in the vein of Marshall (VOM), which ablates the adjacent epicardial tissue to enhance lesion durability.

06

What researchers measure

Primary outcomes

  1. Number of patients with procedural linear bidirectional block

    After first-pass ablation, bidirectional block across the mitral isthmus line will be assessed by conventional methods consisting of differential pacing maneuvers and documenting widely separated double potentials across the entire length of the line and high-density activation mapping with the Optrell catheter. In the case of absence of block, PF applications will be carried out on the RF line where the earliest activation will be evidenced, for an target index of \>550. In the case of absence of block after PF ablation, additional RF and PF ablation points will be performed at the earliest activation sites, adjacent to the previous lesions. A maximum total duration of RF and PF application of 20 min will be allowed for both lines, after which the failure of block will be accepted. Bidirectional conduction block will be reassessed ≥10min after the last ablation lesion along the lines.

    Time frame: During procedure

Secondary outcomes

  1. Procedural safety

    Characterization of complications, including pericardial effusion, stroke and coronary stenosis

    Time frame: 6 months

  2. Procedural parameters: total procedure time (min)

    Comparison of procedural parameters between groups: total procedure time (min)

    Time frame: During procedure

  3. Procedural parameters: fluoroscopy time (min)

    Comparison of procedural parameters between groups: fluoroscopy time (min)

    Time frame: During procedure

  4. Procedural parameters: total RF ablation time (min)

    Comparison of procedural parameters between groups: total RF ablation time

    Time frame: During procedure

  5. Procedural parameters: total ablation time (min)

    Comparison of procedural parameters between groups: total ablation time

    Time frame: During procedure

  6. Procedural parameters: number of ablation lesions required

    Comparison of procedural parameters between groups: number of ablation lesions required

    Time frame: During procedure

  7. Cardiovascular-related hospitalizations

    Characterization of cardiovascular-related hospitalizations in both groups

    Time frame: 6 months

  8. Recurrence of arrhythmia

    Recurrence of arrhythmia, assessed 24 hour Holter monitoring 3 months post procedure and 7-day Holter monitoring 6 months post procedure

    Time frame: 6 months

  9. Quality of life (SF-36 and AF Symtoms Checklist)

    Characterization of quality of life, assessed using the 36-Item Short Form Survey Instrument (SF-36) and the AF Symptom Checklist

    Time frame: 6 months

  10. Left atrial function at 6 months follow-up

    Left atrial function at 6 months follow-up, assessed using transthoracic echocardiography

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jan 2027, 4 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 4 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

Start moved once since we started tracking on Sep 25, 2026: Jul 2025 → Sep 2026, on Oct 26, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2025
First posted
May 8, 2025
StartActual
Sep 24, 2026was Jul 2025
Primary completionEst.
Jan 2027
CompletionEst.
Jul 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 26, 2026
Sites
1 site added — first site in Belgium
Show site
  • AZ Sint-Jan Brugge AV · Bruges, Belgium
Oct 26, 2026
Start date
Jul 2025→Sep 24, 2026 (actual)
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Belgium
    Show site
    • AZ Sint-Jan Brugge AV · Bruges, Belgium
    Start date Jul 2025→Sep 24, 2026 (now actual)
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06962176
Lead sponsor
AZ Sint-Jan AV
Responsible party
Sebastien Knecht (Coordinating investigator, AZ Sint-Jan AV) — Principal investigator
First posted
May 8, 2025
Start date
Sep 24, 2026
Primary completion
Jan 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Emma Christiaen, PhD
Contact
emma.christiaen@azsintjan.be
003250453293
Sébastien Knecht, MD, PhD
principal investigator · AZ Sint-Jan Brugge AV

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion